CA-QUOTIENT-SCIENCES
11.8.2020 14:02:03 CEST | Business Wire | Press release
ANA Therapeutics , a Silicon Valley-based biotech startup, and Quotient Sciences , a leading provider of innovative drug development and manufacturing solutions, today announced a partnership to support the manufacturing of ANA Therapeutics’ drug candidate, ANA001 (niclosamide capsules), which they are developing as a potential treatment for COVID-19. As part of the collaboration, Quotient will scale up the capsule formulation, characterize and optimize the manufacturing process and ensure continuity of drug product through clinical trials.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200811005106/en/
Laboratory experiments have shown niclosamide stops SARS-CoV-2 (the virus that causes COVID-19) from replicating, making it a promising candidate for reducing the spread of COVID-19. Niclosamide was previously approved by the FDA as a treatment for tapeworm and although not currently marketed in the U.S., it is on the World Health Organization’s List of Essential Medicines and has been used for decades to safely treat millions of people around the world.
“We have selected Quotient Sciences as our development and manufacturing partner and our plan is simple,” said Andrew Bartynski , COO, ANA Therapeutics. “Niclosamide has the potential to be an effective antiviral agent to combat COVID-19, and our top goal is to complete a clinical trial to determine its efficacy in treating patients with COVID-19. Quotient’s speed and agility will play a key role in reaching that important milestone.”
Mark Egerton, Ph.D. , CEO of Quotient Sciences, said, “We are proud to partner with ANA Therapeutics in their pursuit of a treatment to fight this coronavirus pandemic. Our experience and flexible manufacturing approaches will enable ANA Therapeutics to initiate clinical testing in an accelerated timeframe.”
Under the scope of the agreement, ANA Therapeutics will access Quotient’s formulation and manufacturing expertise to develop and rapidly supply drug product for pivotal clinical trials in Q3 2020. The program will be conducted at Quotient’s facility in Garnet Valley, Pennsylvania.
About ANA Therapeutics
ANA Therapeutics is a Silicon Valley-based biotech startup working to develop niclosamide as a safe, widely accessible antiviral treatment for patients with COVID-19. A low-cost, scalable, and well-tolerated compound, niclosamide has the potential to be a needed treatment to help individuals who contract the novel coronavirus to beat it.
About Quotient Sciences
Quotient Sciences is an innovative global pharmaceutical development, clinical and commercial manufacturing organization providing services to the pharmaceutical and biotech industries. A combination of specialized skills and agile integrated processes enables Quotient Sciences to develop customized solutions which dramatically reduce the time and cost of getting drugs to market. Everything we do is driven by a deeply held belief, shared across the entire organization, that molecules need to become cures — fast.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005106/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
illumynt Appoints Matt Popieniuck as Vice President of Customer Success & Delivery12.8.2026 14:00:00 CEST | Press release
28-year Dell Technologies veteran, most recently leading services sustainability strategy, joins to own end-to-end program execution as illumynt scales its AI hardware lifecycle business illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Matt Popieniuck has joined the company as Vice President of Customer Success & Delivery, effective August 2026. He reports to CEO Jörg Herbarth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812482293/en/ Matthew Popieniuck, Vice President of Customer Success and Delivery. Popieniuck joins illumynt after 28 years at Dell Technologies, where he progressed from group leadership through senior and principal program management roles before moving into services sustainability strategy. In that most recent chapter, he worked on the question now driving illumynt's market: what happens to enterprise technology after its fi
Ant Group launches AQ for Doctor, bringing an AI-powered workstation to millions of physicians12.8.2026 13:44:00 CEST | Press release
Ant Group today officially upgraded its physician platform, Haodf for Doctor, into AQ for Doctor, an AI-powered workstation designed to support physicians across every stage of clinical practice—from online consultations and patient management to clinical decision support and medical research. The platform is fully integrated with Ant Group's flagship AI health app, AQ, which serves more than 100 million users as of August 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812917154/en/ Ant Group launches AQ for Doctor, bringing an AI-powered workstation to millions of physicians. Connecting doctors and patients through one AI platform "AI will never replace doctors," said Zhang Junjie, Vice President of Ant Group and Head of the Health Business. "But AI can become a trusted assistant for healthcare professionals. Our goal is to build a reliable and practical AI workstation for China's more than five million physicians—
ITC Infotech Strengthens Strategic Tech Partnership With British American Tobacco (BAT) in New Multi-year Mandate12.8.2026 12:30:00 CEST | Press release
ITC Infotech, a leading global technology services and solutions provider, today announced a landmark multi‑year strategic technology deal with British American Tobacco (BAT). Along with BAT, ITC Infotech will accelerate the transformation of BAT’s technology landscape to drive AI-enabled innovation, strengthen skills, and improve efficiencies. In this expanded partnership, ITC Infotech will provide technology services to BAT across Poland, Romania and India. ITC Infotech will also continue to collaborate with BAT to scale capabilities at the newly launched BAT Future Capabilities Centre in India, while supporting BAT’s existing technology hubs in Malaysia and Mexico. This new strategic deal will deepen an already well-established partnership between ITC Infotech and BAT, streamlining end-to-end technology delivery and improving speed, efficiency, and service quality. As part of the deal, ITC Infotech will strengthen its footprint and onshore capabilities in Europe, which will be strat
Gen Z Spending is Expected to Reach $12 Trillion by 2030. Here's Why That Doesn't Matter as Much as Brands Think12.8.2026 12:00:00 CEST | Press release
New NIQ report reveals consumers across generations are trading up and trading down in the same shopping basket, putting new pressure on middle-market products The biggest shift in consumer spending isn't generational—it's behavioral. New research from NielsenIQ (NYSE: NIQ) finds consumers across every age group are increasingly making the same calculation: where is a premium worth paying, and where can they save money instead? The result is a growing divide between premium and value products, while traditional middle-market offerings face mounting pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260812239453/en/ Every generation is spending differently, but all are weighing value more carefully The findings come from NIQ's latest global report, A Tale of Two Consumers: The Polarized Mindsets Reshaping Global Consumption, developed in collaboration with World Data Lab. While Gen X accounted for $15.2 trillion in sp
Kinguin Renews Ravelin Partnership After Cutting Ecommerce Fraud to “Industry-Leading Low”12.8.2026 11:04:00 CEST | Press release
Leading games marketplace extends AI fraud prevention deal for further three years Ravelin automates real-time fraud defenses and supports growth to over 20 million customers Kinguin, a global digital games marketplace serving more than 20 million registered users, has renewed its partnership with AI-native fraud platform Ravelin. The agreement follows significant reductions in fraud and a shift to automated, scalable fraud detection. Since first partnering in 2018, Ravelin has helped Kinguin transform its approach to payment fraud. Kinguin has eliminated the need for real-time manual reviews, while overall fraud rates have declined by 87.5%. The renewal reflects growing confidence in AI-led fraud prevention at a time when ecommerce merchants face increasingly sophisticated attacks, particularly in the digital goods space where instant delivery also means instant results for fraudsters. Kinguin is where gaming and esports fans around the world can access their favorite games, choosing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom